NICE TA487 - for treating chronic lymphocytic leukaemia. (Decision date - December 2017)
NICE TA561 - with rituximab for previously treated chronic lymphocyctic leukaemia. (Decision date - March 2019)
NICE TA663 - Venetoclax with obinutuzumab
for untreated chronic lymphocytic leukaemia. (Decision date - January 2021)
Venetoclax with azacitidine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (Decision date - February 2021)
NICE TA765 - Venetoclax with azacitidine for untreated acute myeloid
leukaemia when intensive chemotherapy is unsuitable. (Decision date - March 2022)
NICE TA787 - Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (Decision date - May 2022)
NICE TA796 - Venetoclax for treating chronic lymphocytic leukaemia. NHSE
commissioned. (Decision date - July 2022)
NHSE commissioned drug.
Red Drug Classifications
1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)